Catalyst Wire Dossier Catalyst Wire Dossier
FDA approval · 2023-07-28

FDA Approved: REBIF — Supplemental Application (EMD Serono, Inc.)

View source ↗

Summary

FDA approved a supplemental application for Rebif (interferon beta-1a) submitted by EMD Serono, Inc.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Rebif (interferon beta-1a)

Snippet

SUPPL AP for REBIF (INTERFERON BETA-1A)